PRGO
Get informed when a big investor buys or sells
+ FollowUndervalued by 85.7% based on the discounted cash flow analysis.
| Market cap | $1.53 Billion |
|---|---|
| Enterprise Value | $5.01 Billion |
| Dividend Yield | $1.16 (10.50%) |
| Earnings per Share | $-10.29 |
| Beta | 0.54 |
| Outstanding Shares | 138,700,000 |
| P/E Ratio | -0.84 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 0.35 |
| Price to Book Ratio | 0.58 |
| Enterprise Value to Revenue | 1.2 |
| Enterprise Value to EBIT | -3.21 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.77 |
| Debt to Equity | 1.53 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2895▼ 15.02% |
|---|---|
| Total Calls | 878,700▼ 11.96% |
| Total Puts | 254,400▼ 42.04% |
Holdings and activity of institutional investors.
| Ownership % | 109.22%▼ 0.57% |
|---|---|
| Total Invested | $1.62B▼ 23.39% |
| Investors Holding | 339▲ 3.00% |
No data
This powerful committee controls taxation, trade policy, and entitlement spending (e.g., Medicare/Medicaid). Tax policy directly impacts profitability, trade policy affects global operations, and Medicare drug pricing decisions are critical for pharmaceutical companies like Perrigo.
This committee directly oversees the FDA, which is the primary regulatory body for pharmaceutical manufacturing, drug approvals, labeling, and safety. Its decisions are fundamental to Perrigo's ability to develop, produce, and sell its products.
This committee's oversight of antitrust laws and intellectual property (IP) is critical for a pharmaceutical company. It impacts M&A activity, generic drug competition, and patent enforcement, which are core to Perrigo's business strategy and profitability.
This committee's jurisdiction over the FTC is highly relevant. The FTC regulates advertising, marketing claims for over-the-counter (OTC) pharmaceutical products, and consumer protection, directly impacting Perrigo's product promotion and compliance.